<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923974</url>
  </required_header>
  <id_info>
    <org_study_id>CPO-2013</org_study_id>
    <nct_id>NCT01923974</nct_id>
  </id_info>
  <brief_title>The Analgesic Effects of Melatonin</brief_title>
  <official_title>The Analgesic Effects of Melatonin: A Randomized, Placebo-controlled, Double-blinded Study on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Peter Holst Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study investigating the analgesic effect of melatonin in a human heat injury model using
      quantitative sensory testing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pain (VAS)</measure>
    <time_frame>During burn injury. 1 hours following melatonin/placebo administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in areas of secondary hyperalgesia</measure>
    <time_frame>1,2,4,6 hours following burn injury, which corresponds to 2,3,5 and 7 hours after melatonin/placebo-administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Areas of secondary hyperalgesia will be assessed by quantitative sensory testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in erythema/oedema assessed by ultrasound</measure>
    <time_frame>1,2,4,6 hours following burn injury, which corresponds to 2,3,5 and 7 hours after melatonin/placebo-administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thermal thresholds assessed by quantitative sensory testing</measure>
    <time_frame>1,2,4,6 hours following burn injury, which corresponds to 2,3,5 and 7 hours after melatonin/placebo-administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical thresholds assessed quantitative sensory testing</measure>
    <time_frame>1,2,4,6 hours following burn injury, which corresponds to 2,3,5 and 7 hours after melatonin/placebo-administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Analgesia</condition>
  <condition>Antihyperalgesia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV formulation, Melatonin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV formulation, Melatonin 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 10 mg</intervention_name>
    <arm_group_label>Melatonin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 100 mg</intervention_name>
    <arm_group_label>Melatonin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged between 20 and 40 years

        Exclusion Criteria:

          -  Under aged/minors

          -  Does not speak or understand danish

          -  Alcohol or abuse of medicines

          -  Prior QST-trial within the last 2 month

          -  Prior medical trail within the last month

          -  Serious comorbidity (ASA-class 3-4)

          -  Chronic pain (defined by analgesic treatment) Shift-work or night work within the
             last 14 days Known sleep-disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars P.H. Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars P.H. Andersen, MD</last_name>
    <phone>4531518908</phone>
    <email>lphandersen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multidisciplinary Pain Center 7612, Neuroscience Center, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars P.H. Andersen, M.D.</last_name>
      <phone>31518908</phone>
      <email>lphandersen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Lars Peter Holst Andersen</investigator_full_name>
    <investigator_title>Ph.d. fellow</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
